Skip to main content

Advertisement

SpringerLink
Log in

Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to evaluate the association of race/ethnicity, patient care experiences (PCEs), and receipt of definitive treatment and treatment modality among older adults in the United States (US) with localized prostate cancer (PCa).

Methods

Using Surveillance, Epidemiology and End Results dataset linked to Medicare Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) for 2007–2015, we identified men aged ≥ 65 years who completed a CAHPS survey within one year before and one year after PCa diagnosis. Associations of race/ethnicity (non-Hispanic White (NHW), non-Hispanic Black (NHB), Hispanic, non-Hispanic Asian (NHA), and other) and of interactions between race/ethnicity and PCEs (getting needed care, getting care quickly, doctor communication, and care coordination) with the receipt of definitive PCa treatment and treatment modality within 3 and 6 months of diagnosis were examined using logistic regressions.

Results

Among 1,438 PCa survivors, no racial/ethnic disparities in the receipt of definitive treatment were identified. However, NHB patients were less likely to receive surgery (vs. radiation) within 3 and 6 months of PCa diagnosis than NHW patients (OR 0.397, p = 0.006 and OR 0.419, p = 0.005), respectively. Among NHA patients, a 1-point higher score for getting care quickly was associated with lower odds (OR 0.981, p = 0.043) of receiving definitive treatment within 3 months of PCa diagnosis, whereas among NHB patients, a 1-point higher score for doctor communication was associated with higher odds (OR 1.023, p = 0.039) of receiving definitive treatment within 6 months of PCa diagnosis.

Discussion

We observed differential associations between PCEs and receipt of definitive treatment based on patient race/ethnicity. Further research is needed to explore these associations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The datasets used to conduct this study are available upon approval of a research protocol from the National Cancer Institute. Instructions for obtaining these data are available at https://healthcaredelivery.cancer.gov/seer-cahps/obtain/required.html.

References

  1. Surveillance Epidemiology and End Results (SEER) (2021) Prostate Cancer - Cancer Stat Facts. Retrieved October 4, 2022, from https://seer.cancer.gov/statfacts/html/prost.html

  2. Arcangeli S, Pinzi V, Arcangeli G (2012) Epidemiology of Prostate cancer and treatment remarks. World J Radiol 4(6):241. https://doi.org/10.4329/WJR.V4.I6.241

    Article  PubMed  PubMed Central  Google Scholar 

  3. D’Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick,G. A., … Wein, A. (1998). Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer. JAMA, 280(11), 969–974. https://doi.org/10.1001/JAMA.280.11.969

  4. National Cancer Institute (2021) Prostate Cancer Treatment (PDQ®)–Health Professional Version - National Cancer Institute. Retrieved September 2, 2021, from https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq

  5. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO), & American Urological Association (2017) Prostate Cancer: Clinically Localized Guideline - American Urological Association. Retrieved September 2, 2021, from https://www.auanet.org/guidelines/guidelines/prostate-cancer-clinically-localized-guideline

  6. Moses KA, Orom H, Brasel A, Gaddy J, Underwood W (2017) Racial/Ethnic disparity in treatment for Prostate Cancer: does Cancer Severity Matter. Urology 99:76. https://doi.org/10.1016/J.UROLOGY.2016.07.045

    Article  PubMed  Google Scholar 

  7. Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M.,… Nguyen, P. L. (2014). Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups.Urology, 84(2), 386–392. https://doi.org/10.1016/J.UROLOGY.2014.05.009

  8. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC (2013) Racial differences in time from Prostate cancer diagnosis to treatment initiation: a population-based study. Cancer 119(13):2486–2493. https://doi.org/10.1002/cncr.27975

    Article  PubMed  Google Scholar 

  9. Cole, A. P., Herzog, P., Iyer, H. S., Marchese, M., Mahal, B. A., Lipsitz, S. R.,… Trinh, Q.-D. (2021). Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer, 127(15), 2714–2723. https://doi.org/10.1002/cncr.33564

  10. Xiao H, Tan F, Goovaerts P, Adunlin G, Ali A, Huang Y, Gwede CK (2013) Factors Associated with Time-to-treatment of Prostate Cancer in Florida. J Health Care Poor Underserved 24(4 0):132. https://doi.org/10.1353/HPU.2014.0005

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nguyen, D. D., Haeuser, L., Paciotti, M., Reitblat, C., Cellini, J., Lipsitz, S. R.,… Trinh, Q. D. (2021). Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? The Journal of urology, 205(5), 1263–1274. https://doi.org/10.1097/JU.0000000000001601

  12. Van Den Bergh RCN, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, Van Der Poel HG (2013) Timing of curative treatment for Prostate Cancer: a systematic review. Eur Urol 64(2):204–215. https://doi.org/10.1016/J.EURURO.2013.02.024

    Article  PubMed  PubMed Central  Google Scholar 

  13. Laukhtina, E., Sari Motlagh, R., Mori, K., Quhal, F., Schuettfort, V. M., Mostafaei,H., … Shariat, S. F. (2021). Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World Journal of Urology, 39(11), 4085–4099. https://doi.org/10.1007/S00345-021-03703-8/TABLES/3

  14. The CAHPS Program | Agency for Healthcare Research and Quality. (n.d.). Retrieved January 26 (2021) from https://www.ahrq.gov/cahps/about-cahps/cahps-program/index.html

  15. Navarro S, Hu X, Mejia A, Ochoa CY, Pickering TA, Ballas L, Farias AJ (2022) Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of Prostate cancer: a SEER-CAHPS study. Cancer Causes & Control: CCC 33(4):601–612. https://doi.org/10.1007/S10552-022-01552-3

    Article  PubMed  Google Scholar 

  16. Farias AJ, Ochoa CY, Toledo G, Bang SI, Hamilton AS, Du XL (2020) Racial/ethnic differences in patient experiences with health care in association with earlier stage at Breast cancer diagnosis: findings from the SEER-CAHPS data. Cancer Causes Control. https://doi.org/10.1007/s10552-019-01254-3

    Article  PubMed  Google Scholar 

  17. Farias AJ, Toledo G, Ochoa CY, Hamilton AS (2021) Racial/ethnic disparities in patient experiences with Health Care in Association with earlier stage at Colorectal Cancer diagnosis: findings from the SEER-CAHPS Data. Med Care 59(4). https://doi.org/10.1097/MLR.0000000000001514

  18. Schwei RJ, Johnson TP, Matthews AK, Jacobs EA (2017) Perceptions of negative Health Care experiences and Self-reported Health Behavior Change in 3 racial and ethnic groups. Ethn Health 22(2):156. https://doi.org/10.1080/13557858.2016.1244621

    Article  PubMed  Google Scholar 

  19. Chawla, N., Urato, M., Ambs, A., Schussler, N., Hays, R. D., Clauser, S. B., … Arora,N. K. (2015). Unveiling SEER-CAHPS®: A New Data Resource for Quality of Care Research.Journal of General Internal Medicine, 30(5), 641–650. https://doi.org/10.1007/s11606-014-3162-9

  20. National Cancer Institute. (n.d.). CAHPS Data Documentation. Retrieved March 24 (2022) from https://healthcaredelivery.cancer.gov/seer-cahps/aboutdata/documentation.html

  21. National Cancer Institute. (n.d.). Overview of the SEER Program. Retrieved March 24 (2022) from https://seer.cancer.gov/about/overview.html

  22. National Cancer Institute. (n.d.). About the SEER-CAHPS Database. Retrieved January 13, 2020, from https://healthcaredelivery.cancer.gov/seer-cahps/overview/

  23. Bonfill, X., Martinez-Zapata, M. J., Vernooij, R. W. M., Sánchez, M. J., Morales-Suárez-Varela,M., Emparanza, J. I., … Cebollada, M. M. (2021). Follow-up care over 12 months of patients with prostate cancer in Spain: A multicenter prospective cohort study. Medicine, 100(47). https://doi.org/10.1097/MD.0000000000027801

  24. National Comprehensive Cancer Network (NCCN) (2020) Prostate Cancer Early Stage. Retrieved from https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf

  25. Bagley, A. F., Anscher, M. S., Choi, S., Frank, S. J., Hoffman, K. E., Kuban, D. A., … Tang, C. (2020). Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Network Open, 3(3), e201255–e201255. https://doi.org/10.1001/JAMANETWORKOPEN.2020.1255

  26. National Cancer Institute (2020) SEER-CAHPS Analytic Guidance. Retrieved February 15, 2020, from https://healthcaredelivery.cancer.gov/seer-cahps/researchers/approaches_guidance.html

  27. National Cancer Institute (NCI) (2020) SEER-CAHPS Case-Mix Adjustment Guidance. Retrieved from https://healthcaredelivery.cancer.gov/seer-cahps/researchers/guidance.html

  28. Kan, C. K., Qureshi, M. M., Gupta, A., Agarwal, A., Gignac, G. A., Bloch, B. N., …Hirsch, A. E. (2018). Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Advances in Radiation Oncology, 3(2), 181–189. https://doi.org/10.1016/J.ADRO.2017.12.002

  29. Wang X (2014) Firth logistic regression for rare variant association tests. Frontiers in Genetics, 5(JUN). https://doi.org/10.3389/FGENE.2014.00187

  30. Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, Epstein JI (2012) Treatment decision-making for localized Prostate Cancer: what younger men choose and why. Prostate 72(1):58. https://doi.org/10.1002/PROS.21406

    Article  PubMed  Google Scholar 

  31. Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2017) Patient-physician communication and health-related quality of life of patients with localised Prostate cancer undergoing radical prostatectomy - a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://doi.org/10.1111/BJU.13495

    Article  PubMed  Google Scholar 

  32. Sheppard, V. B., Isaacs, C., Luta, G., Willey, S. C., Boisvert, M., Harper, F. W.K., … Mandelblatt, J. S. (2013). Narrowing Racial Gaps in Breast Cancer Chemotherapy Initiation: The Role of the Patient-Provider Relationship. Breast cancer research and treatment, 139(1), 207. https://doi.org/10.1007/S10549-013-2520-3

  33. Jiang Y, Sereika SM, Bender CM, Brufsky AM, Rosenzweig MQ (2016) Beliefs in chemotherapy and knowledge of cancer and treatment among African American women with newly diagnosed Breast cancer. Oncol Nurs Forum 43(2). https://doi.org/10.1188/16.ONF.180-189

  34. Chao, G. F., Krishna, N., Aizer, A. A., Dalela, D., Hanske, J., Li, H., … Trinh, Q.D. (2016). Asian Americans and prostate cancer: A nationwide population-based analysis.Urologic oncology, 34(5), 233.e7-233.e15. https://doi.org/10.1016/J.UROLONC.2015.11.013

  35. Wilson S, Billones H (1994) The Filipino elder: implications for nursing practice. Knowledge of heritage essential. J Gerontol Nurs 20(8):31–36. https://doi.org/10.3928/0098-9134-19940801-07

    Article  CAS  PubMed  Google Scholar 

  36. Hu X, Ye H, Yan W, Sun Y (2022) Factors Associated with Patient’s refusal of recommended Cancer Surgery: based on Surveillance, Epidemiology, and end results. Front Public Health 9:2361. https://doi.org/10.3389/FPUBH.2021.785602/BIBTEX

    Article  Google Scholar 

  37. Fang, P., He, W., Gomez, D., Hoffman, K. E., Smith, B. D., Giordano, S. H., … Smith,G. L. (2018). Racial disparities in guideline-concordant cancer care and mortality in the United States. Advances in Radiation Oncology, 3(3), 221. https://doi.org/10.1016/J.ADRO.2018.04.013

  38. Presley, C. J., Raldow, A. C., Cramer, L. D., Soulos, P. R., Long, J. B., Yu, J. B.,… Abuse and Mental Health Services Administration, S. (2013). A new approach to understanding racial disparities in prostate cancer treatment. Cancer, 126(1), 1–8. https://doi.org/10.1016/j.jgo.2012.07.005

  39. SEER Treatment Data Limitations (November 2021 Submission) - SEER Data & Software. (n.d.). Retrieved November 22 (2022) from https://seer.cancer.gov/data-software/documentation/seerstat/nov2021/treatment-limitations-nov2021.html

  40. National Cancer Institute. (n.d.). Survey Weights. Retrieved April 18 (2022) from https://healthcaredelivery.cancer.gov/seer-cahps/researchers/weights.html

  41. Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., … Neal,D. E. (2016). Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 375(15), 1425–1437. https://doi.org/10.1056/NEJMOA1606221/SUPPL_FILE/NEJMOA1606221_DISCLOSURES.PDF

  42. Gordon BBE, Basak R, Carpenter WR, Usinger D, Godley PA, Chen RC (2019) Factors influencing Prostate cancer treatment decisions for African-American and caucasian men. Cancer 125(10):1693–1700. https://doi.org/10.1002/CNCR.31932

    Article  PubMed  Google Scholar 

  43. Wenzel, M., Nocera, L., Collà Ruvolo, C., Würnschimmel, C., Tian, Z., Shariat, S.F., … Karakiewicz, P. I. (2021). Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. The Journal of urology, 206(1), 69–79. https://doi.org/10.1097/JU.0000000000001695

  44. Dembosky, J. W., Haviland, A. M., Haas, A., Hambarsoomian, K., Weech-Maldonado, R.,Wilson-Frederick, S. M., … Elliott, M. N. (2019). Indirect Estimation of Race/Ethnicity for Survey Respondents Who Do Not Report Race/Ethnicity. Medical Care, 57(5), E28–E33. https://doi.org/10.1097/MLR.0000000000001011

Download references

Acknowledgements

The authors would like to thank Adrian Jemal Williams for helping to finalize and publish this manuscript.

Funding

CL was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1 TR003107-02S2. Support of data acquisition was provided by the Arkansas Biosciences Institute, the major research component of the Arkansas Tobacco Settlement Proceeds Act of 2000. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, National Cancer Institute, or Arkansas Biosciences Institute.

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, 72205, USA

    Ambrish A. Pandit, Laura E Gressler, Nalin Payakachat & Chenghui Li

  2. Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Dr., Bethesda, MD, 20892-9762, USA

    Michael T. Halpern

  3. Department of Surgery, College of Medicine, University of Cincinnati, Medical Sciences Building, 231 Albert Sabin Way Suite 2501, Cincinnati, OH, 45267, USA

    Mohamed Kamel

  4. Department of Urology, Ain Shams University, Cairo, 11566, Egypt

    Mohamed Kamel

Authors
  1. Ambrish A. Pandit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura E Gressler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nalin Payakachat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chenghui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AP, MH, LG, MK, NP, and CL contributed to the study conceptualization, analysis, and interpretation of results. The first draft of the manuscript was written by AP and revised critically for important intellectual content by MH, LG, MK, NP, and CL. The final draft of the manuscript was read and approved by all authors.

Corresponding author

Correspondence to Chenghui Li.

Ethics declarations

Conflicts of interest

The authors have no conflicts of interests to declare. CL received research support for unrelated projects sponsored by University of Utah/AstraZeneca.

Ethnic approval

This research was determined to be non-Human subject research by University of Arkansas for Medical Sciences Institutional Review Board (IRB # 260675).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1: Appendix

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pandit, A.A., Halpern, M.T., Gressler, L.E. et al. Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study. Cancer Causes Control 35, 647–659 (2024). https://doi.org/10.1007/s10552-023-01834-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-023-01834-4

Keywords

Search

Navigation